CDX2 and mucin protein expressions were examined and compared with survival and adjuvant chemotherapy benefits in a prospective evaluation cohort of 782 stage II/III gastric adenocarcinoma patients. This evidence concerns the gene CDX2 and gastric adenocarcinoma.